Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLORENZI, Adriana T.
dc.contributor.authorFREGNANI, Jose Humberto T.
dc.contributor.authorPOSSATI-RESENDE, Julio Cesar
dc.contributor.authorANTONIAZZI, Marcio
dc.contributor.authorSCAPULATEMPO-NETO, Cristovam
dc.contributor.authorSYRJANEN, Stina
dc.contributor.authorVILLA, Luisa L.
dc.contributor.authorLONGATTO-FILHO, Adhemar
dc.date.accessioned2016-12-20T16:36:51Z
dc.date.available2016-12-20T16:36:51Z
dc.date.issued2016
dc.description.abstractBACKGROUNDHuman papillomavirus (HPV) DNA testing can be crucial for women who have limited access to traditional screening. The current study compared the results obtained through HPV DNA testing with those obtained through cytology-based screening. METHODSA total of 3068 women aged 18 to 85 years were enrolled in an opportunistic cervical cancer screening program developed by the Barretos Cancer Hospital and performed by a team of health professionals working within a mobile unit from March to December 2012, followed by statistical analyses. For each patient, 2 different cervical samples were collected and preserved in a careHPV assay and SurePath medium, respectively. RESULTSHigh-risk HPV (hr-HPV) DNA was detected in 10.0% of women, with the majority (86.7%) demonstrating no abnormal Papanicolaou test results. The following cytological samples were found to be hr-HPV positive: 8.2% of the normal samples; 39.4% of the samples with atypical squamous/glandular cells of undetermined significance; 38.5% of the samples with atypical squamous/glandular cells of undetermined significance, cannot exclude high-grade lesion; 55.3% of the samples with low-grade squamous intraepithelial lesions; and 100% of the samples with high-grade squamous intraepithelial lesions. Colposcopy examinations were performed among 33.4% of the women with positive results on at least 1 of the tests (HPV DNA positive and/or cytology with atypical squamous/glandular cells of undetermined significance, cannot exclude high-grade lesion or high-grade squamous intraepithelial lesions), and 59.5% of these women underwent biopsies. Among these samples, 18.2% were confirmed as cervical intraepithelial neoplasia. CONCLUSIONSThe careHPV test was demonstrated to be a feasible alternative to primary screening in low-resource settings accessed through the use of mobile units. Cancer Cytopathol 2016;124:581-8. (c) 2016 American Cancer Society. The human papillomavirus (HPV) DNA test is an important tool that is used to improve screening programs. The HPV DNA test allows for the detection of early HPV-induced lesions in women, thereby enabling clinicians to provide the best possible follow-up.
dc.description.indexMEDLINE
dc.description.sponsorshipBarretos Cancer Hospital
dc.identifier.citationCANCER CYTOPATHOLOGY, v.124, n.8, p.581-588, 2016
dc.identifier.doi10.1002/cncy.21718
dc.identifier.eissn1934-6638
dc.identifier.issn1934-662X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/17047
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofCancer Cytopathology
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY-BLACKWELL
dc.subjectcancer screening
dc.subjectcervical cancer
dc.subjectcolposcopy
dc.subjecthuman papillomavirus (HPV) DNA tests
dc.subjectPapanicolaou test
dc.subject.otherhuman-papillomavirus dna
dc.subject.otherself-collected specimens
dc.subject.other3+and cervical-cancer
dc.subject.otherhybrid capture 2
dc.subject.otherundetermined significance
dc.subject.otherpositive women
dc.subject.othersquamous-cells
dc.subject.other5-year risks
dc.subject.otherchina
dc.subject.otherpapanicolaou
dc.subject.wosOncology
dc.subject.wosPathology
dc.titleCan the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryFinlândia
hcfmusp.affiliation.countryisofi
hcfmusp.author.externalLORENZI, Adriana T.:Barretos Canc Hosp, Pio Fdn 12, Inst Educ & Res, Sao Paulo, Brazil; Barretos Canc Hosp, Pio Fdn 12, Ctr Mol Oncol, Sao Paulo, Brazil
hcfmusp.author.externalFREGNANI, Jose Humberto T.:Barretos Canc Hosp, Pio Fdn 12, Inst Educ & Res, Sao Paulo, Brazil; Barretos Canc Hosp, Pio Fdn 12, Ctr Mol Oncol, Dept Researcher Support, Sao Paulo, Brazil
hcfmusp.author.externalPOSSATI-RESENDE, Julio Cesar:Barretos Canc Hosp, Pio Fdn 12, Inst Educ & Res, Sao Paulo, Brazil; Barretos Canc Hosp, Pio Fdn 12, Ctr Mol Oncol, Dept Prevent, Sao Paulo, Brazil
hcfmusp.author.externalANTONIAZZI, Marcio:Barretos Canc Hosp, Pio Fdn 12, Inst Educ & Res, Sao Paulo, Brazil; Barretos Canc Hosp, Pio Fdn 12, Ctr Mol Oncol, Dept Prevent, Sao Paulo, Brazil
hcfmusp.author.externalSCAPULATEMPO-NETO, Cristovam:Barretos Canc Hosp, Pio Fdn 12, Ctr Mol Oncol, Sao Paulo, Brazil; Barretos Canc Hosp, Pio Fdn 12, Ctr Mol Oncol, Dept Pathol, Sao Paulo, Brazil
hcfmusp.author.externalSYRJANEN, Stina:Univ Turku, Fac Med, Inst Dent, Medicity Res Lab, Turku, Finland; Univ Turku, Fac Med, Inst Dent, Dept Oral Pathol, Turku, Finland; Turku Univ, Cent Hosp, Dept Pathol, Turku, Finland
hcfmusp.citation.scopus16
hcfmusp.contributor.author-fmusphcLUISA LINA VILLA
hcfmusp.contributor.author-fmusphcADHEMAR LONGATTO FILHO
hcfmusp.description.beginpage581
hcfmusp.description.endpage588
hcfmusp.description.issue8
hcfmusp.description.volume124
hcfmusp.origemWOS
hcfmusp.origem.pubmed27070446
hcfmusp.origem.scopus2-s2.0-84982135194
hcfmusp.origem.wosWOS:000382859900010
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceArbyn M, 2012, VACCINE, V30, pF88, DOI 10.1016/j.vaccine.2012.06.095
hcfmusp.relation.referenceAyres Andréia Rodrigues Gonçalves, 2010, Rev. Saúde Pública, V44, P963
hcfmusp.relation.referenceBecker E, 2001, DIAGN CYTOPATHOL, V24, P276, DOI 10.1002/dc.1059
hcfmusp.relation.referenceCampos NG, 2014, AM J EPIDEMIOL, V180, P545, DOI 10.1093/aje/kwu159
hcfmusp.relation.referenceCastle PE, 2012, J CLIN ONCOL, V30, P3044, DOI 10.1200/JCO.2011.38.8389
hcfmusp.relation.referenceCastle PE, 2012, VACCINE, V30, pF117, DOI 10.1016/j.vaccine.2012.05.071
hcfmusp.relation.referenceChen W, 2014, J CLIN VIROL, V61, P553, DOI 10.1016/j.jcv.2014.09.018
hcfmusp.relation.referencede Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
hcfmusp.relation.referenceDiaz ML, 2013, OBSTET GYN CLIN N AM, V40, P391, DOI 10.1016/j.ogc.2013.02.003
hcfmusp.relation.referenceDijkstra MG, 2014, CANCER EPIDEM BIOMAR, V23, P55, DOI 10.1158/1055-9965.EPI-13-0173
hcfmusp.relation.referenceDoorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
hcfmusp.relation.referenceEntiauspe LG, 2014, BRAZ J MICROBIOL, V45, P689, DOI [10.1590/S1517-83822014005000047, 10.1590/S1517-83822014000200043]
hcfmusp.relation.referenceFakokunde B, 2008, INT J GYNECOL OBSTET, V101, P245, DOI 10.1016/j.ijgo.2007.11.014
hcfmusp.relation.referenceFernandes JV, 2009, INT J GYNECOL OBSTET, V105, P21, DOI 10.1016/j.ijgo.2008.12.004
hcfmusp.relation.referenceForman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
hcfmusp.relation.referenceGage JC, 2014, CANCER CYTOPATHOL, V122, P842, DOI 10.1002/cncy.21463
hcfmusp.relation.referenceInstituto Nacional do Cancer/National Cancer Institute (INCA), CANC BRAZ DAT POP BA
hcfmusp.relation.referenceJeronimo J, 2015, J LOW GENIT TRACT DI, V19, P220, DOI 10.1097/LGT.0000000000000088
hcfmusp.relation.referenceKang LN, 2014, J CLIN MICROBIOL, V52, P1954, DOI 10.1128/JCM.03432-13
hcfmusp.relation.referenceKatki HA, 2013, J LOW GENIT TRACT DI, V17, pS36, DOI 10.1097/LGT.0b013e3182854253
hcfmusp.relation.referenceKatki HA, 2013, J LOW GENIT TRACT DI, V17, pS56, DOI 10.1097/LGT.0b013e318285437b
hcfmusp.relation.referenceLabani S, 2014, EUR J OBSTET GYN R B, V181, P233, DOI 10.1016/j.ejogrb.2014.08.005
hcfmusp.relation.referenceLabani S, 2016, J EPIDEMIOL COMMUN H, V70, P72, DOI 10.1136/jech-2015-205851
hcfmusp.relation.referenceLin CQ, 2014, J VIROL METHODS, V202, P73, DOI 10.1016/j.jviromet.2014.03.002
hcfmusp.relation.referenceLongatto-Filho A, 2007, DIAGN CYTOPATHOL, V35, P672, DOI 10.1002/dc.20700
hcfmusp.relation.referenceLorenzi AT, 2013, GYNECOL ONCOL, V131, P131, DOI 10.1016/j.ygyno.2013.07.092
hcfmusp.relation.referenceLouvanto K, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.12.033
hcfmusp.relation.referenceMayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430
hcfmusp.relation.referenceMoyer VA, 2012, ANN INTERN MED, V156, P880, DOI 10.7326/0003-4819-156-12-201206190-00424
hcfmusp.relation.referenceNonnenmacher B, 2002, REV SAUDE PUBL, V36, P95, DOI [10.1590/S0034-89102002000100015, 10.1590/s0034-89102002000100015]
hcfmusp.relation.referenceNoronha VL, 2011, J BRAS DOENCAS SEX T, V23, P5, DOI 10.5533/2177-8264-201123103
hcfmusp.relation.referencePaengchit K, 2014, ASIAN PAC J CANCER P, V15, P7951, DOI 10.7314/APJCP.2014.15.18.7951
hcfmusp.relation.referencePoljak M, 2012, VACCINE, V30, pF100, DOI 10.1016/j.vaccine.2012.04.105
hcfmusp.relation.referenceQiagen, 2008, CAREHPV TEST TRAIN G
hcfmusp.relation.referenceQiao YL, 2014, INT J CANCER, V134, P2891, DOI 10.1002/ijc.28616
hcfmusp.relation.referenceQiao YL, 2008, LANCET ONCOL, V9, P929, DOI 10.1016/S1470-2045(08)70210-9
hcfmusp.relation.referenceRosa MI, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.033
hcfmusp.relation.referenceRositch AF, 2013, INT J CANCER, V133, P1271, DOI 10.1002/ijc.27828
hcfmusp.relation.referenceSaayman F, 2013, INT J GYNECOL OBSTET, V120, P257, DOI 10.1016/j.ijgo.2012.09.022
hcfmusp.relation.referenceSankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516
hcfmusp.relation.referenceSaslow D, 2012, CA-CANCER J CLIN, V62, P147, DOI 10.3322/caac.21139
hcfmusp.relation.referenceSchiffman M, 2015, J CLIN MICROBIOL, V53, P52, DOI 10.1128/JCM.02116-14
hcfmusp.relation.referenceSchmitt FC, 2008, J CLIN PATHOL, V61, P258, DOI 10.1136/jcp.2006.044347
hcfmusp.relation.referenceTahseen S, 2008, EUR J OBSTET GYN R B, V139, P90, DOI 10.1016/j.ejogrb.2007.09.001
hcfmusp.relation.referencede Aguiar SRV, 2014, J MED VIROL, V86, P1528, DOI 10.1002/jmv.23972
hcfmusp.relation.referenceWorld Health Organization, 2014, COMPR CERV CANC CONT
hcfmusp.relation.referenceWorld Health Organization and International Agency for Research on Cancer, CERV CANC EST INC MO
hcfmusp.relation.referenceZhao FH, 2013, CANCER PREV RES, V6, P938, DOI 10.1158/1940-6207.CAPR-13-0091
hcfmusp.relation.referenceZhao FH, 2012, CANCER EPIDEMIOL, V36, P384, DOI 10.1016/j.canep.2012.01.009
hcfmusp.relation.referenceZhao FH, 2012, J NATL CANCER I, V104, P178, DOI 10.1093/jnci/djr532
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicatione9db2534-e0d7-4b2e-b4aa-c3be7faf01d5
relation.isAuthorOfPublication4401f59e-efe8-4a24-9f39-0b6bde3c72b7
relation.isAuthorOfPublication.latestForDiscoverye9db2534-e0d7-4b2e-b4aa-c3be7faf01d5
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_LORENZI_Can_the_careHPV_test_performed_in_mobile_units_2016.PDF
Tamanho:
191.73 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03